BridgeMD
Tests treatment safety and results for Cancer Of Pancreas
Official title Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients
ClinicalTrials.gov ID: NCT06046794
What this study is testing
- What it's testing
- The goal of this interventional study is to learn about the efficacy of first-line chemotherapy with Gemcitabine in metastatic pancreatic adenocarcinoma patients expressing the GemCore signature in their tumor. The main question it aims to answer is to assess efficacy of Gemcitabine (tumor response, survival rate) in the population of patient bearing the GemCore signature.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Metastatic pancreatic adenocarcinoma histological proved
- FOLFIRINOX chemotherapy-ineligible patient and going to receive first-line metastatic chemotherapy with gemcitabine monotherapy
- Tumor material allowing assessment of GEMCore status (i.e. FFPE block with tumor cellularity ≥ 10%);
- Life expectancy \> 2 months;
- Measurable target according to RECIST 1.1 criteria;
You likely can't join if
- Contraindication to Gemcitabine treatment;
- ECOG performance status ≥ 3;
- Person in emergency situation or unable to express non-opposition;
- Patient under a legal protection measure (adult under guardianship, curatorship or safeguard of justice);
- Unable to undergo medical follow-up for geographical, social or psychological reasons.
See the full eligibility criteria
- Metastatic pancreatic adenocarcinoma histological proved
- FOLFIRINOX chemotherapy-ineligible patient and going to receive first-line metastatic chemotherapy with gemcitabine monotherapy
- Tumor material allowing assessment of GEMCore status (i.e. FFPE block with tumor cellularity ≥ 10%);
- Life expectancy \> 2 months;
- Measurable target according to RECIST 1.1 criteria;
- No previous treatment in metastatic situation;
- Age ≥ 18 years;
- Patient not opposed to study participation;
- Affiliation to a social security system, or beneficiary of such a scheme.
- Contraindication to Gemcitabine treatment;
- ECOG performance status ≥ 3;
- Person in emergency situation or unable to express non-opposition;
- Patient under a legal protection measure (adult under guardianship, curatorship or safeguard of justice);
- Unable to undergo medical follow-up for geographical, social or psychological reasons.
The study team makes the final eligibility decision.
Where it's taking place
- Marseille, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Marseille, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.